Introduction
Auto-SCT is an important treatment option for selected patients with hematological malignancies. However, the high doses of chemotherapy used for the preparatory regimens before transplantation leave patients at risk of neutropenic complications, such as fungal and bacterial infections, that in rare cases can be fatal. [1] [2] [3] In addition, it has been shown that the duration of grade 4 neutropenia in the post transplant setting has a major effect on overall morbidity and mortality. [4] [5] Filgrastim is a recombinant human G-CSF that stimulates the production of neutrophil precursors and thereby reduces the duration of neutropenia and associated complications. 6 Various studies have shown that the administration of filgrastim post transplant significantly reduces the time to neutrophil recovery. 5, [7] [8] For this reason, administration of filgrastim after SCT has become a standard practice at many institutions to hasten neutrophil recovery. 9 Filgrastim, dosed at 5 mcg/kg/day, requires daily s.c. administration because of its short half-life and renal clearance. [9] [10] Alternatively, pegfilgrastim is a long-acting formulation of filgrastim that is dosed as a single 6-mg dose and has a significantly increased half-life in part because of a decreased renal clearance. Neutrophil receptor binding is also an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. Thus, the concentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery. [10] [11] [12] The use of filgrastim vs pegfilgrastim in the auto-SCT population has been studied after high-dose melphalan in multiple myeloma patients. There were no differences in duration of grade 4 neutropenia or time to neutrophil and platelet recovery. However, the incidence and duration of febrile neutropenia were lower in the pegfilgrastim arm. The study concluded that pegfilgrastim could be used safely with similar efficacy in that patient population. 13 Staber et al.
14 retrospectively analyzed 24 patients who received pegfilgrastim after 30 transplants vs 30 patients who received filgrastim post transplant, and showed no difference in the incidence of febrile neutropenia or toxicity in patients with various hematological malignancies, including acute leukemia. However, the mean duration of grade 4 neutropenia and the duration of febrile neutropenia were shorter in the pegfilgrastim arm. Again, the investigators concluded that filgrastim and pegfilgrastim showed comparable safety and efficacy.
On the basis of the evidence of comparable efficacy presented within these clinical trials, 3 years ago we implemented a practice change from daily filgrastim to a single dose of pegfilgrastim for patients undergoing autologous transplant. In this paper, we report a retrospective study of our experience with the primary objective of comparing the engraftment rates between these two agents in this setting. Secondary objectives included comparing the efficacy and safety of both agents.
Patients and methods

Study design
We collected data on 164 consecutive adult patients who received an auto-SCT between January 2006 and November 2007. During the first half of the study period, 82 consecutive patients at Memorial Sloan-Kettering Cancer Center received filgrastim beginning day þ 5 after transplant. A practice change was implemented, and for the second half of the study we collected data from 82 consecutive patients who received pegfilgrastim on day þ 1 after transplant resulting in an equal number of patients in each cohort. Institutional guidelines allowed patients receiving a single dose of pegfilgrastim to receive additional doses of filgrastim based on physician discretion.
Data collection
Approval for this retrospective evaluation was granted from our Institutional Review Board, and the information was gathered from the patient's electronic medical record and the pharmacy database. Data collection included baseline characteristics, time to neutrophil recovery with ANC of X500 once, incidence of febrile neutropenia, number of days of severe neutropenia (ANC p100), total days with an ANC o500, number of doses of filgrastim and pegfilgrastim given, reported episodes of bone pain, incidence of engraftment syndrome, number of definitive infections (defined as a positive culture) and days of i.v. antibiotics (all patients received oral prophylactic antibiotics, antivirals and antifungals before the start of the conditioning regimen). We also conducted a formal cost analysis between the two groups.
Cost analysis methodology
All professional and hospital charges, and the associated quantities accrued during the transplant admission, were captured from Memorial Sloan-Kettering Cancer Center's centralized computer billing system. Charges and quantities were collected by date of service and department at the billing unit level. These included physicians' fees, blood bank, pharmacy, laboratory, supplies, radiology, diagnostic imaging, respiratory therapy, physical therapy, and room and board charges among others. Since the study spanned 2 years, all charges were converted to 2008 prices to adjust for charge increases implemented during the course of the study. This was carried out at the billing unit level by multiplying the unit quantities by the 2008 unit price. Original unit prices and quantities were analyzed to assure that changes in the base unit level would not affect the adjustment to 2008 prices. Six drugs with changes in the billing units were identified, and conversion factors were calculated. The original quantities were multiplied by these factors to achieve 2008 equivalent billing unit quantities, then the conversion to 2008 charges was carried out. The adjusted charges were then converted to cost, using a ratio of cost to charges derived from the institutional cost report for 2008, to comply with institutional policies on the publication of cost data. Ratio of cost to charges are unique to each institution and department, and vary from year to year. The adjusted costs were then summed to yield an adjusted cost per patient. Costs per patient were examined for the entire transplant admission, as well as from the day of the transplant to discharge. In addition, costs were examined at the departmental level to look for variation in expenditures associated with pegfilgrastim treatment.
Statistical analysis
The Wilcoxon rank-sum test (for continuous variables) or Fisher's exact test (for categorical variables) was used to assess differences in the pegfilgrastim and filgrastim groups. Other data were analyzed using descriptive statistics.
Results
Baseline characteristics
A total of 164 patients receiving auto-SCT from January 2006 to November 2007 were retrospectively reviewed. There were 82 patients in both the filgrastim and pegfilgrastim cohorts of the study. Baseline characteristics of the patients were well balanced in both study groups with detailed demographics presented in Table 1 . There were no statistically significant differences in age, gender or CD34 þ cell doses transplanted. In all, 19 patients had received a previous autologous transplant in the filgrastim cohort compared with 11 patients in the pegfilgrastim cohort; however, this difference was not statistically significant.
Neutrophil recovery
Time to engraftment, defined as the time to reach an ANC X500 once after the day of auto-SCT, was 10.9 days with filgrastim compared with 9.6 days with pegfilgrastim (Po0.0001) (Figure 1 ). The total number of days with an ANC o500 was 7.6 days with filgrastim vs 6.4 days with pegfilgrastim (Po0.001). When comparing the total days of severe neutropenia (ANC p100), there were 6.6 days of severe neutropenia with filgrastim compared with 6 days with pegfilgrastim (P ¼ 0.06).
Infection risk and use of anti-infectives
The incidence of febrile neutropenia was 78% with filgrastim compared with 59% with pegfilgrastim (P ¼ 0.012) (Figure 2 ). The duration of febrile neutropenia was not significantly reduced, but was an average of 3.2 days with filgrastim and 2.5 days with pegfilgrastim (P ¼ 0.08). The total number of antibiotic days was shorter for the patients who received pegfilgrastim, being 18.2 days with pegfilgrastim vs 20.4 days with filgrastim (P ¼ 0.045).
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Days of treatment with i.v. antibiotics were also less with pegfilgrastim, 6.3 days compared with 9.6 with filgrastim (P ¼ 0.006) (Figure 3 ). The incidence of positive cultures was 32% with filgrastim vs 23% with pegfilgrastim (P ¼ 0.294).
Doses of filgrastim and pegfilgrastim
Patients in the filgrastim cohort received an average of nine daily injections of filgrastim (ranging from 5 to 21 daily doses). In total, 76 of the 82 patients in the pegfilgrastim cohort received only the single dose of pegfilgrastim, while 6 patients received additional filgrastim. Four patients received one additional dose of filgrastim and two patients received two additional doses of filgrastim. However, all six patients received these additional doses from 1 to 10 days after they had already engrafted, and these patients all engrafted within 12 days of their transplant (Table 2) .
Cost assessment A cost analysis of the post transplant period showed decreased costs for patients receiving pegfilgrastim, with the largest cost savings per patient being room and board and laboratory with a savings of $6,499/patient and $789/patient, respectively (Table 3) . Total cost savings per patient receiving pegfilgrastim was $8283, which represented a 13.3% reduction in the total post transplant costs. The largest cost increase in patients receiving 
Table 2
Additional
doses of filgrastim (G-CSF) in pegfilgrastim patients
Patient
Day of engraftment Day(s) of G-CSF Table 4) . The bulk of the cost savings related to decreased length of stay as the average length of hospitalization after patients received their autologous stem cells (that is, excluding the days of myeloablative chemotherapy) was 17 days with filgrastim compared with 14.9 days with pegfilgrastim (P ¼ 0.049) (Figure 4) . We compared the number of chest X-rays and computed tomography scans between both cohorts and although the fewer number of radiologic exams per patient did not reach statistical significance in the pegfilgrastim group, there was a cost savings associated with the decreased use of radiologic tests (Table 3) .
Toxicity
Two pegfilgrastim patients had documented bone pain compared with none of the patients who received filgrastim. Engraftment syndrome occurred in one patient in each group. There was one transplant-related death in the filgrastim group, unrelated to the use of filgrastim.
Discussion
The high doses of chemotherapy before auto-SCT leave patients at risk of neutropenic complications. In our study of 164 patients, we found faster neutrophil engraftment, fewer neutropenic fevers and 410% cost savings with the use of pegfilgrastim. Patients receiving pegfilgrastim after stem cell infusion engrafted 1 day sooner than patients receiving daily injections of filgrastim. As the ANC nadir does not occur immediately after myeloablative chemotherapy, we also compared the total number of days patients had an ANC o500. Patients receiving pegfilgrastim had 1 day less with an ANC o500 compared with patients receiving filgrastim (6.4 days vs 7.6 days, Po0.001). In addition, our results show a trend toward statistical significance between filgrastim and pegfilgrastim on the number of days of severe neutropenia (ANC p100).
The incidence of febrile neutropenia was nearly 20% lower in pegfilgrastim patients. Variables such as prophylactic anti-infectives used, the preparatory chemotherapy regimens patients received, or the average CD34 þ cell dose were similar in both groups and therefore cannot account for this difference. Thus, this difference is most likely due to faster engraftment in the patients receiving pegfilgrastim. The lower incidence of febrile neutropenia in pegfilgrastim patients in turn led to the use of fewer anti-infectives (excluding all prophylactic anti-infectives initiated per transplant guidelines). This includes not only fewer days of i.v. anti-infectives (6.4 days vs 9.6 days) but also fewer numbers of patients needing additional anti-infectives aside from prophylaxis. Twenty-seven patients in the pegfilgrastim cohort were not given additional i.v. anti-infectives while only 10 patients in the filgrastim cohort went through the post transplant period without receiving additional i.v. antiinfectives.
Only a few of the patients who received pegfilgrastim were given additional doses of filgrastim. In fact, the pegfilgrastim patients who received additional doses of filgrastim all engrafted within 12 days of their transplant, and they received these additional doses after they had already engrafted, which calls into question the need for additional doses of filgrastim in these patients. The administration of these doses of filgrastim within the pegfilgrastim group were at the discretion of the attending physician, however, the reasons for its use cannot be consistently determined (although in one case persistent fever led to its use). An additional consideration when comparing these agents is the convenience of a single From the perspective of patient comfort, nursing administration and pharmacy preparation, administration of a single dose is preferable. Overall, there were no differences in toxicity with these two agents. Bone pain was reported twice with pegfilgrastim and unreported with filgrastim. No other toxicities were attributed to these agents based on chart reviews.
Previously published data comparing the use of pegfilgrastim and filgrastim have generally concluded that pegfilgrastim is a safe and equally efficacious alternative to filgrastim. Jagasia et al. 15 studied the use of pegfilgrastim given on day þ 1 in 38 multiple myeloma and lymphoma patients after autologous transplantation. They found a similar, relatively low incidence of febrile neutropenia (49%), however, they found no difference in the time to neutrophil engraftment when compared with a historical filgrastim control group. Vanstraelen et al. found no significant difference in neutrophil engraftment (8 vs 9 days with pegfilgrastim and filgrastim, respectively) or incidence of fever in 20 patients receiving pegfilgrastim when compared with a filgrastim historical control. However, they found significantly higher values of lymphocytes and neutrophils up to day 100 in the pegfilgrastim group. 16 Although this had no effect on clinical outcomes, other studies have suggested that faster lymphocyte recovery may be associated with improved outcome after autologous transplantation; these studies have generally included large numbers of patients. [17] [18] [19] Ballestrero et al.
20
reported results comparing filgrastim and pegfilgrastim after autologous transplant in patients with solid tumors and lymphomas. Growth factor support was initiated on day þ 5 for both groups in this study (according to a delayed administration schedule) and no differences were found in hematological recovery or neutropenic fever; patients receiving pegfilgrastim did have a lower incidence of grade III to IV mucositis. Overall, these studies show equivalent or at times faster (but not statistically significant) neutrophil recovery with pegfilgrastim. Our study was larger than these previous trials, and our results showed both faster engraftment and lower rates of febrile neutropenia with the use of pegfilgrastim. Clearly, additional studies of pegfilgrastim are warranted to confirm our findings. Currently, the use of pegfilgrastim is only reimbursed in the out-patient setting. Therefore, cost analysis is necessary to justify the use of pegfilgrastim within the in-patient setting because its use will not be reimbursed in the hospital. In this study, we conducted a formalized cost analysis to compare the use of these two agents and found significant savings with the use of pegfilgrastim. Fewer days of hospitalization, days of i.v. antibiotics and neutropenic fevers resulted in decreased costs for room and board, radiology and antibiotics with a total savings of over $8000 per patient. In addition to cost savings, the clinical benefit of fewer days in the hospital in terms of possible iatrogenic problems is also quite important. The average wholesale price (reported by commercial publishers of drug pricing data) of a single 6-mg dose of pegfilgrastim in 2009 is $3918.75. Although this figure does not represent the acquisition cost for pegfilgrastim, because institutions purchase brand name drugs for a marked percentage below average wholesale price, it does reflect the higher initial cost of pegfilgrastim. 21 However, despite this initial cost, our cost analysis justifies the use of this agent within our institution.
Conclusions
The limitations of this analysis include its retrospective single-institution study design. In addition, toxicities can be difficult to accurately assess through chart review. Nonetheless, patients receiving pegfilgrastim had faster engraftment and less febrile neutropenia. In addition, these patients required fewer days of anti-infectives and hospitalization. We conclude that a single dose of pegfilgrastim is a safe and efficacious alternative to daily injections of filgrastim and is a cost-effective approach in auto-SCT patients. Validation of these results requires a prospective, multicenter clinical trial.
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